New 2026 ACC/AHA Dyslipidemia Guideline for cardiovascular disease risk assessment

Dyslipidemia is defined as an abnormal pattern of lipids (fats) in the bloodstream, most commonly involving elevated LDL cholesterol, elevated triglycerides, low HDL cholesterol, or other abnormal lipid markers such as non-HDL cholesterol, apoB, or lipoprotein(a). It is a major, often silent, driver of atherosclerotic cardiovascular disease: excess atherogenic lipid particles (i.e. LDL) can enter artery walls, promote inflammation and plaque formation (which clogs the artery), and ultimately increase the risk of coronary artery disease, heart attack, stroke, and peripheral artery disease. Because dyslipidemia usually causes no symptoms until vascular disease is advanced, routine lipid screening is important for early detection. It is also clinically important because it is a modifiable risk factor; lifestyle changes and lipid-lowering medications such as statins can substantially reduce future cardiovascular events.

 

Traditionally, LDL has been the focus because it is the main atherogenic (atherosclerosis-causing) lipoprotein in the blood. However, other apolipoprotein B (apoB) containing lipoprotein particles can also enter the artery wall contributing to atherosclerotic plaque. This is where the biomarkers non-HDL cholesterol and apoB comes into play and the two terms are somewhat interchangeable; the apoB particles are exactly the same group of lipoprotein particles that carry non-HDL cholesterol. ApoB is a key protein found on the surface of cholesterol-carrying lipoprotein particles in your blood.

Non-HDL cholesterol (Non-HDL-C) is defined as the cholesterol carried by all lipoproteins except HDL. It is calculated from a standard lipid panel: Non-HDL-C = Total cholesterol − HDL-C.

Medically, non-HDL-C is important because it describes the cholesterol carried by all the main atherogenic particles and not just LDL; these include LDL, VLDL, IDL, triglyceride-rich remnant particles, and lipoprotein(a), all of which contain apoB. Physiologically what makes HDL different is that HDL particles collect excess cholesterol from peripheral tissues and the walls of the blood vessels, and carries the cholesterol back to the liver, where it is broken down and excreted from the body via bile. This is essentially the reverse of what all the atherogenic non-HDL lipid particles do.

There are certain scenarios in which non-HDL-C can reflect cardiovascular risk better than LDL-C alone, especially when triglycerides are elevated, as in diabetes, insulin resistance, obesity, metabolic syndrome, or mixed dyslipidemia. In those settings, LDL-C may look only mildly abnormal while VLDL and remnant particles are also contributing significantly to atherosclerosis risk.

Given the need for an update, in March, the American College of Cardiology (ACC), American Heart Association (AHA), and nine other medical organizations issued the new 2026 ACC/AHA Dyslipidemia Guideline that replaced the 2018 guideline on the management of blood cholesterol. The older 2018 U.S. ACC/AHA "blood cholesterol" guideline focused heavily on LDL-C, statin intensity, percentage LDL reduction, and 10-year ASCVD risk estimated with the Pooled Cohort Equations. The newer 2026 guideline broadens the scope to dyslipidemia more generally, including LDL-C, non-HDL-C, triglycerides, remnant particles, apoB, and lipoprotein(a), and replaces the older risk calculator with the PREVENT-ASCVD equations, which estimate both 10-year and 30-year risk in adults ages 30–79. In practical terms, the change is from "estimate 10-year risk and choose statin intensity" to "estimate both short- and long-term risk, personalize risk using factors such as CAC (coronary artery calcium score), Lp(a), apoB, diabetes, kidney disease, and family history, and treat earlier or more intensively when overall lifetime cardiovascular risk is high."

There are several reasons for the change. First, atherosclerosis is increasingly understood as the consequence of cumulative exposure to cholesterol-containing particles over many years. An LDL level that is moderately elevated for 30 or 40 years may cause more damage than a higher level that is present for only a short period. This has led to the "lower for longer" principle: lowering LDL earlier in life should prevent more plaque from forming than waiting until a person becomes old enough to have a high 10-year risk. Second, as described above, LDL cholesterol does not capture every form of lipid-related risk. Third, there are now more effective nonstatin treatments, making it possible to reach lower cholesterol goals when statins alone are insufficient or cannot be tolerated. 

From a technical perspective, the new guideline replaces the Pooled Cohort Equations (PCE) with the AHA’s Predicting Risk of Cardiovascular Disease EVENTs, or PREVENT-ASCVD, equations. The older Pooled Cohort Equations estimated the probability of a first heart attack or stroke during the next 10 years for an adult between ages 40 and 79. The relevant variables included age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood-pressure treatment, smoking, and diabetes. PREVENT-ASCVD applies to adults ages 30 to 79 and calculates both 10-year and 30-year ASCVD risk. It eliminates race from the equation and uses a broader cardiovascular-kidney-metabolic profile that includes age, sex, non-HDL cholesterol, HDL cholesterol, systolic blood pressure, smoking, diabetes, body mass index, kidney function measured by estimated glomerular filtration rate, and the use of blood-pressure and lipid-lowering medications. Optional inputs such as hemoglobin A1c, urine albumin-to-creatinine ratio, and a neighborhood-level Social Deprivation Index can further refine the estimate. 

In addition, PCE was built using data from only about 25,000 people from older studies (decades ago), and generated separate equations for Black and White adults. PREVENT was derived from about 3.28 million contemporary adults and externally validated in another 3.33 million. As a result, the PREVENT model possesses superior agreement between predicted and observed risk (calibration). For example, we now know that the PCE 10 year risk was an overestimate because the older data do not reflect the improved health of a modern population. 

For the typical patient, the new guideline will refine the treatment regimen rather than replace it. Lifestyle measures -- including a healthy dietary pattern, regular physical activity, weight management, avoidance of tobacco, adequate sleep, and control of blood pressure and diabetes -- remain the foundation of treatment. When medication is appropriate, a statin will usually remain the first drug prescribed. The practical difference is that the clinician will now calculate PREVENT risk, consider a specific LDL-C and non-HDL-C goal, and monitor whether the patient reaches that goal. The routine evaluation may also include a once-in-a-lifetime Lp(a) measurement, while apoB testing may be useful when triglycerides are elevated, diabetes or metabolic syndrome is present, or LDL-C appears satisfactory despite suspected residual risk. If the decision to begin treatment is uncertain, coronary artery calcium imaging may show whether the patient has already developed coronary plaque.

The PREVENT-ASCVD calculator places the patient into one of four 10-year risk categories as shown in Table 1. At a borderline 10-year risk of 3% to <5% (chance of heart attack or stroke), a moderate-intensity statin is reasonable after discussing risk enhancers and preferences. At intermediate risk of 5% to <10%, at least a moderate-intensity statin is recommended, generally aiming for a 30%–49% LDL-C reduction and an LDL-C <100 mg/dL. At high risk of at least 10%, a high-intensity statin is recommended, aiming for at least a 50% reduction and an LDL-C <70 mg/dL. 

Table 1. PREVENT-ASCVD 10-Year Risk Categories. Risk score is the probability of a first heart attack or stroke during the next 10 years (ChatGPT).

Patients who do not reach their LDL goal on a tolerated statin may also receive more active treatment than under the older 2018 regimen. The clinician may increase the statin dose or add another drug, commonly ezetimibe, which reduces intestinal cholesterol absorption. Bempedoic acid offers an oral option for some patients who cannot tolerate adequate statin therapy, while injectable PCSK9-directed drugs can produce much larger LDL reductions in patients at high risk or with inherited hypercholesterolemia. People with established ASCVD are most likely to receive intensive combination therapy because many will now have an LDL-C goal below 55 mg/dL. Thus, a hallmark of the new guidelines is more stringent LDL-C goals for higher risk patients that are now achievable through recent LDL lowering medicines.

The 30-year risk assessment tool is explicitly intended for younger adults aged 30 to 59 who present with a low 10-year risk score (<3%). It is possible that their 30-year risk is much higher, and this longer-term perspective can make a major difference for the younger person. For example, consider a 38-year-old with elevated LDL cholesterol, mildly high blood pressure, and a family history of premature heart disease. Because age exerts a large effect on short-term cardiovascular risk, the older model might calculate a low probability of a heart attack or stroke before age 48. That result could support a “watch and wait” approach. The PREVENT model may still calculate a low 10-year risk, but its 30-year estimate can reveal a much greater probability of an event before age 68 e.g. ≥ 10%. In that elevated long-term risk category, a moderate-intensity statin reasonable even when 10-year risk is low (see Table 2).

Table 2. PREVENT-ASCVD 10-Year Risk Categories (ChatGPT).

Importantly, the new guideline does not rely on the calculator alone. It recommends a "calculate, personalize, and reclassify" (CPR) risk refinement framework in which the PREVENT estimate is supplemented by risk-enhancing factors such as family history, elevated Lp(a), chronic inflammatory disease, pregnancy-related risk factors, or chronic kidney disease:

• C - Calculate: Run the baseline 10-year PREVENT-ASCVD risk score (followed by 30-year risk score).
• P - Personalize: Assess variables excluded from the calculator, such as family history, reproductive risk markers, Lp(a) measurement, and persistently elevated high-sensitivity C-reactive protein (chronic inflammation).
• R - Reclassify & Reassess: Selectively utilize Coronary Artery Calcium (CAC) scoring to reclassify risk for borderline or intermediate patients and finalize the treatment plan.

If uncertainty remains after the "C" and "P" steps, coronary artery calcium (CAC) scanning can determine whether calcified atherosclerotic plaque is already present. A CAC score of zero may support deferring medication in an otherwise lower-risk person with no higher-risk condition, whereas any CAC favors treatment, especially at higher scores.

In summary, the overall message of the 2026 guideline is that cholesterol management should begin earlier, consider more than LDL alone, and continue across the lifespan with stringent goals. The older approach was largely concerned with whether a middle-aged patient’s 10-year risk was high enough to justify starting a statin. Now there is a more explicit attempt to match the intensity and timing of treatment to absolute risk, lifetime exposure, additional risk markers, and patient preference. A particular focus is reducing the cumulative burden of atherogenic lipoproteins over a longer time horizon i.e. 30 years. For many patients, the answer will still be healthy behavior plus a statin. The difference is that clinicians now have a more modern risk calculator, clearer treatment targets, additional biomarkers, and a larger selection of drugs with which to pursue the goal of keeping harmful cholesterol particles lower for longer.